PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.48%
Negative revenue growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-7.46%
Negative gross profit growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-24.95%
Negative EBIT growth while Medical - Pharmaceuticals median is 1.11%. Seth Klarman would check if external or internal factors caused the decline.
-28.32%
Negative operating income growth while Medical - Pharmaceuticals median is 1.41%. Seth Klarman would check if structural or cyclical issues are at play.
-25.47%
Negative net income growth while Medical - Pharmaceuticals median is 2.19%. Seth Klarman would investigate factors dragging net income down.
-25.47%
Negative EPS growth while Medical - Pharmaceuticals median is 3.88%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-25.47%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 3.88%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.02%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.05%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
56.07%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 23.06%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
64.73%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 12.77%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
32.48%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 10.46%. Joel Greenblatt might see a short-term competitive advantage at play.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
126.36%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 24.06% over a decade. Joel Greenblatt might see a standout compounder of earnings.
101.74%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 7.11%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
77.60%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 8.94%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
195.62%
Equity/share CAGR of 195.62% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
123.30%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 3.62%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
57.64%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 11.09%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
266.67%
5Y dividend/share CAGR of 266.67% while Medical - Pharmaceuticals is zero. Walter Schloss sees at least some improvement that could compound over time.
144.44%
3Y dividend/share CAGR of 144.44% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
-3.70%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
5.46%
Inventory growth of 5.46% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
-0.01%
Assets shrink while Medical - Pharmaceuticals median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
3.68%
BV/share growth exceeding 1.5x Medical - Pharmaceuticals median. Joel Greenblatt checks if consistent ROE or undervalued buybacks fuel this advantage.
-5.56%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
0.60%
SG&A growth of 0.60% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.